This webinar discusses how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients. Paolo A. Ascierto, MD of Italy’s National Tumor Institute and Kamil Sklodowski of Biognosys elaborate on the promise of proteomics for addressing the unmet medical needs of melanoma patients undergoing immunotherapy.

GenomeWebinar June 16, 2021
Precision Oncology in Melanoma Patients Treated with Immunotherapy: Clinical and Technological Perspective

Poster presented at ASBMB 2022

Presenter: Nigel Beaton
Monday, August 15

The fusion of trapped ion mobility spectrometry (TIMS) with parallel reaction monitoring (PRM), particularly through the prm-PASEF ® technique, is indeed a groundbreaking development in proteomics. This innovative approach leverages the parallel accumulation-serial fragmentation (PASEF) mode to synchronize ion release from TIMS with selective precursor isolation, reducing the noise in the peptide ion spectra without sacrificing sensitivity.

Poster presented at ESMO 2022

 
Authors: Domenico Mallardo, Christoph Messner, Mariaelena Capone, Jakob Vowinckel, Antonio Sorrentino, Karel Novy, Vito Vanella, Kristina Beeler, Sarah Warren, Paolo Ascierto
Presenter: Domenico Mallardo (Istituto Nazionale Tumori Fondazione G Pascale, Napoli, Italy)

Date: September 10

E-Poster presented at AACR 2020

Presenter: Kristina Beeler, PhD
A collaboration with: Istituto Nazionale Tumori IRCCS Fondazione G. Pascale

Numerous software tools, including Spectronaut, have been developed to interpret the increasingly complex and voluminous raw data generated from mass-spectrometry-based proteomics data. These resulting datasets are typically extensive and challenging to analyze, necessitating substantial expertise in the field of proteomics.

This poster emphasizes the importance of MHC molecules in immune responses, particularly in cancer research, where comprehending tumor-associated antigens holds great significance. Accurately quantifying HLA class I/II neoantigens is essential for understanding how the immune system detects and reacts to cancerous cells. However, a significant limitation lies in the high input material requirement.

We devised an integrated immunopeptidomics (IMPX) workflow tailored for cell and tissue samples to address this challenge. This innovative approach allows for in-depth profiling of immunopeptides while substantially reducing the input material needed, which is particularly beneficial for PBMC samples.

E-Poster presented at AACR 2020

Presenter: Kristina Beeler, PhD
A collaboration with: Cancer Research UK Cambridge Institute

Various studies in the last years have shown that using SRM/MRM has the potential to identify hundreds of biomarker candidates in one study (Mermelekas, 2015). However, panel development remains asignificant bottleneck in the adoption of targeted proteomics.

New: Spectronaut^® 19

Unlock Your Data's True Story

New: Spectronaut^® 19

Unlock Your Data's True Story

Learn More